Effectiveness of Antiretroviral Therapy after Protease Inhibitor Failure: An Analytic Overview
Open Access
- 1 June 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (11) , 1613-1622
- https://doi.org/10.1086/420930
Abstract
To examine effectiveness of subsequent antiretroviral therapy (ART), studies published during the period of 1 January 1997 through 31 May 2003 involving patients who had failed a protease inhibitor (PI)-containing regimen and were switched to another regimen were reviewed. Twelve studies describing 1197 patients were analyzed. A total of 38% of patients had human immunodeficiency virus (HIV) RNA levels of <500 copies/mL at 24 weeks. After adjustment for baseline HIV RNA level, the rate of virologic suppression ranged from 16% for patients switching drugs within previously failed classes to 54% for nonnucleoside reverse-transcriptase inhibitor (NNRTI)-naive patients switched to boosted PI- and NNRTI-containing regimens. ART regimens in patients who failed a PI-containing regimen provided virologic suppression only in a few patients. The best response was seen in NNRTI-naive patients receiving NNRTI- and boosted PI-containing regimens. New approaches are needed to achieve better suppression in pretreated HIV-infected patients.Keywords
This publication has 76 references indexed in Scilit:
- Treatment with Indinavir, Efavirenz, and Adefovir after Failure of Nelfinavir TherapyThe Journal of Infectious Diseases, 2003
- Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with RitonavirAntimicrobial Agents and Chemotherapy, 2002
- Extent of Human Immunodeficiency Virus Type 1 Drug Resistance as a Predictor of Virological Failure after Genotype‐Guided Treatment SwitchClinical Infectious Diseases, 2001
- Initial Virological and Immunologic Response to Highly Active Antiretroviral Therapy Predicts Long‐Term Clinical OutcomeClinical Infectious Diseases, 2001
- Long‐term benefit of genotypic‐guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patientsJournal of Clinical Laboratory Analysis, 2001
- Phenotypic Drug Susceptibility Testing Predicts Long‐Term Virologic Suppression Better than Treatment History in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2001
- Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359The Journal of Infectious Diseases, 2000
- A Clinical Study of the Combination of 100 mg Ritonavir plus 800 mg Indinavir as Salvage Therapy: Influence of Increased Plasma Drug Levels in the Rate of ResponseHIV Research & Clinical Practice, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- A meta-analysis of condom effectiveness in reducing sexually transmitted HIVSocial Science & Medicine, 1993